TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption.
2021
Denise C Hsu | Alexandra Schuetz | Rawiwan Imerbsin | Decha Silsorn | Amarendra Pegu | Dutsadee Inthawong | Jumpol Sopanaporn | Pornsuk Visudhiphan | Weerawan Chuenarom | Boot Keawboon | Wei Shi | Merlin L Robb | John R Mascola | Romas Geleziunas | Richard A Koup | Dan H Barouch | Nelson L Michael | Sandhya Vasan
Toll-like receptor 7 (TLR7) agonist and PGT121 (broadly neutralizing antibody, bnAb) administration previously delayed viral rebound and induced SHIV remission. We evaluated the impact of GS-986 (TLR7 agonist) and dual bnAbs on viral rebound after antiretroviral therapy (ART) interruption. Rhesus macaques inoculated with SHIV-1157ipd3N4 were initiated on daily suppressive ART from Day 14 post SHIV inoculation. Active arm animals (n = 8) received GS-986, N6-LS and PGT121 after plasma viral suppression, starting from week 14. GS-986 induced immune activation and SHIV-specific T cell responses but not viral expression in all the active arm animals. After ART interruption, median time to viral rebound was 6 weeks in the active and 3 weeks in the control arm (p = 0.024). In this animal model, the administration of the combination of GS-986 and dual bnAbs was associated with a modest delay in viral rebound. This strategy should be further evaluated to better understand the underlying mechanisms for the induction of virus-specific immune responses and delay in viral rebound.
显示更多 [+] 显示较少 [-]